Barnsfather Kris, Pietrantoni Marcello
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, USA.
J Reprod Med. 2007 Aug;52(8):737-40.
Recurrent unexplained pregnancy loss plagues obstetricians. Many therapies are controversial, including intravenous immunoglobulin (IVIG). There have been limited studies to support or oppose its use.
A 33-year-old woman, gravida 12, para 0, 2, 10, 1, with normal laboratory values and normal parental karyotypes, unsuccessfully tried many different accepted therapies for recurrent pregnancy loss. She tried IVIG with the last pregnancy and achieved delivery of a viable, male infant at 32 weeks' gestation.
For many cases of unexplained recurrent pregnancy loss, IVIG may not be the answer. However, this case may demonstrate a limited role for IVIG in the treatment of recurrent pregnancy loss with repeated maternal floor infarction of the placenta. Deciding whether or not to use IVIG should not be the question; the real question may be when to use it.
复发性不明原因妊娠丢失困扰着产科医生。许多治疗方法存在争议，包括静脉注射免疫球蛋白（IVIG）。支持或反对使用它的研究有限。
一名33岁女性，孕12产0、2、10、1，实验室检查值正常，父母染色体核型正常，尝试了许多不同的公认的复发性妊娠丢失治疗方法但均未成功。她在最后一次妊娠时尝试了IVIG，并在妊娠32周时分娩出一名存活的男婴。
对于许多不明原因的复发性妊娠丢失病例，IVIG可能不是答案。然而，该病例可能表明IVIG在治疗伴有反复胎盘母体面梗死的复发性妊娠丢失中作用有限。决定是否使用IVIG不应是问题所在；真正的问题可能是何时使用它。
